Skuid, the leading no-code cloud application platform, today announced that TissueTech, a distinguished biotechnology company and leader in regenerative amniotic tissue-based products, has selected Skuid to accelerate its sales process and decision-making with a custom, mobile-capable configure-price-quote (CPQ) app.
To better match customer needs, TissueTech developed a more complex pricing structure based on tier systems and unit quantities. To better support its sales teams, TissueTech needed a made-to-order business application to make the new pricing model simple to implement.
The app had to use dynamic, complex, conditional logic, yet present options to sales people in a simple, elegant user interface that would eliminate errors and deliver accurate quotes to customers quickly and efficiently. TissueTech needed the new CPQ app completed within a couple months.
Due to constrained IT resources and a very tight deadline, they did not have the option of writing custom code according to a traditional development process.
Plus, they needed to create a system that required little to no maintenance, with changes able to be implemented by business users without help from IT.
Because of their unique pricing model and business needs, no off-the-shelf CPQ solution would work. TissueTech worked with a Skuid consulting partner, SaaSli, based in Toronto, Ontario. SaaSli completed the first version of the app in just one week.
TissueTech went live with the completed CPQ app just 6 weeks after the start of the project. The completely custom CPQ experience TissueTech built with Skuid can accommodate complex pricing rules, aggregate data from multiple, disparate sources, and present all relevant information within a simple, easy-to-use interface.
The app works on any web browser, mobile device, or even a chatbot.“We built the app with Skuid in less time that we had spent with another development firm just doing discovery,” said Ian Vargas, Director, Sales System & Customer Service at TissueTech.
“Clearly, the simplicity of Skuid won us over, and now we can maintain the app ourselves. We needed a platform that would grow with us, and we’re already looking at future plans to use the Skuid Platform in other areas of the company.”
Skuid was founded in 2013 on the simple belief that enterprise software should stop forcing people to behave like machines. Instead, apps should behave more like the humans who use them, so everyone can thrive in the digital world.
With Skuid’s simple-to-use but incredibly robust cloud front-end design-and-deploy platform, anyone can connect to disparate data sources, assemble highly complex, made-to-order applications, and instantly make changes, all without writing code.
More than 5 million users across 32 countries use Skuid to engage with each other, with data, and with new customers in meaningful ways. For more information, visit www.skuid.com.
TissueTech, Inc., the parent company of Amniox Medical Inc. and Bio-Tissue, Inc., pioneered the development and clinical application of regenerative, amniotic tissue-based products.
Amniox Medical markets products for use in the musculoskeletal and wound care markets; Bio-Tissue markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 30 continuous years of research grants.
Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform.